Extensive genomic analysis in patients with KRAS -mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.
Ida Christine JacobsenIben SpanggaardMartin HøjgaardLaïla BelcaidCamilla QvortrupChristina Westmose YdeAne Yde SchmidtFinn Cilius NielsenGro Linno WillemoeMikkel Seidelin DamUlrik LassenKristoffer Staal RohrbergPublished in: Acta oncologica (Stockholm, Sweden) (2022)
-mutated solid tumors may contribute with information to the genomic landscape of cancers and identify targets for immunotherapy or synthetic lethality drugs, but currently appears to have overall limited clinical impact, as few patients received targeted therapy matched to their GP.